Generated by AI
Nyxoah SA is a medical technology company focused on developing and commercializing solutions for obstructive sleep apnea, a common sleep-disordered breathing condition. Nyxoah’s lead product is the Genio system, a patient-centered hypoglossal neurostimulation therapy designed to help treat moderate to severe obstructive sleep apnea. The company operates in the healthcare equipment and neuromodulation space, serving a medical market that relies on minimally invasive technologies to address chronic respiratory and sleep-related disorders. Nyxoah SA is headquartered in Mont-Saint-Guibert, Belgium, and its current business centers on bringing sleep apnea treatment alternatives to clinical practice through its proprietary Genio platform.
WebsiteRue Edouard Belin 12
Mont-Saint-Guibert, 1435
Belgium
The latest articles about NYXH.
INSIDE INFORMATIONREGULATED INFORMATION Nyxoah Obtains Default Decision Against Inspire Medical Systems in Unified Patent Court Case Mont-Saint-Guibert, Belgium – November 18, 2026, 8:00 am CET / 2:00 am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Court of First Instance of the Unified Patent Court (UPC
Nyxoah SA (NYXH) posted 29% sequential U.S. revenue growth and strong AXIS study results, but trimmed its 2026 outlook as it awaits FDA review of the Genio CCC indication.
Summary of Sep 3's posts. Generated by AI.
No summary yet.
Summary of Apr 8's posts. Generated by AI.
Summary of Aug 11's posts. Generated by AI.
No summary yet.
Summary of Aug 18's posts. Generated by AI.
Investors talking about NYXH also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.